Hypera S.A (HYPE3)
B3 Stock Exchange · Brazil · prices in BRL · close of 23 Oct 2026
Key indicators
| Last close | BRL 27.25 |
|---|---|
| 52-week range | 19.88 – 30.00 |
| Return, 1 month / 3 months | +11.8% / +35.6% |
| Return, 1 year / 3 years | +21.7% / −9.8% |
| Trend | Uptrend |
| RSI (14) | 67 |
| Volatility (1 year) | 32.8% |
| Worst drawdown (1 year) | -25.3% |
| Average daily value traded | 84.80M BRL |
| Dividend yield | 2.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Hypera is a Brazilian pharmaceutical company based in São Paulo. It develops, makes and sells branded prescription medicines, over-the-counter remedies and consumer health products, covering areas such as pain relief, respiratory care, dermatology and nutrition. Its customers are pharmacies, drugstore chains, hospitals and consumers across Brazil, and it markets its products under a range of household brand names in the medicines and personal care aisles.
Hypera S.A trades under the code HYPE3 on the B3 Stock Exchange in Brazil, with its price quoted in Brazilian reais (BRL). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Hypera S.A (HYPE3) trades on the B3 Stock Exchange in Brazil. It last closed at BRL 27.25 on 23 October 2026.
Its price-based Market X-Ray is 73 out of 100 (a strong price profile), ranking 95 of 1,455 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 21.7% and over the last three months it rose 35.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on B3 Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 78 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 20.4% | ||
| From 52-week high | -1.2% | ||
| Momentum | 74 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 35.6% | ||
| 6-month return | 20.3% | ||
| 12-month return, skipping the last month | 8.9% | ||
| Stability (higher is calmer) | 63 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 32.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -25.3% | ||
| Liquidity | 94 · Strong | Trades actively. | |
| Average daily value traded | 84.80M BRL | ||
| Zero-volume days | 0.0% | ||
| Income | 47 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.0% | ||
| Years with dividends | 6 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +6.4% |
|---|---|
| 1 month | +11.8% |
| 3 months | +35.6% |
| 6 months | +20.3% |
| 1 year | +21.7% |
| 3 years | −9.8% |
| 5 years | +16.4% |
Signals
| 50-day / 200-day average | 23.44 / 22.64 |
|---|---|
| Golden / death cross (60 days) | Golden, 9 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.99 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 31 Mar 2026 | BRL 0.2630 |
| 26 Dec 2025 | BRL 0.2925 |
| 26 Sep 2025 | BRL 0.2925 |
| 26 Jun 2025 | BRL 0.2925 |
| 27 Mar 2025 | BRL 0.2925 |
| 27 Dec 2024 | BRL 0.2908 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on B3 Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.